tepotinib
merck
['nsclc', 'tepotinib', 'sclc']
proud to have contributed to this year s asco! patients with egfr mutant (m) met-altered nsclc receiving tepotinib with an egfr tyrosine kinase inhibitor (tki): a case series. j clin oncol 41, 2023 (suppl 16; abstr 9070). doi 10.1200/jco.2023.41.16_suppl.907 
pulmonologist/thoracic oncologist